Itzhak D. Goldberg
Equibles does not estimate personal net worth.
About Itzhak D. Goldberg
Earlier roles on record: Chairman at Elicio Therapeutics, Inc. (ELTX) until December 31, 2021. Elicio Therapeutics, Inc. reported in an 8-K filed June 2, 2023 that Itzhak D. Goldberg resigned as member of Angion's board of directors, effective June 1, 2023. The proxy statement of Elicio Therapeutics, Inc. reports total compensation of $1,247,881 for Itzhak D. Goldberg in fiscal 2021, including a base salary of $484,018.
“each of Victor F. Ganzi, J.D., Itzhak D. Goldberg, M.D. and Gilbert S. Omenn, M.D., Ph.D., resigned from Angion's board of directors and any respective committee membership of Angion's board of directors, effective as of the effective time of Merger”
Affiliation history
-
Start not stated–2021-12-31
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Elicio Therapeutics, Inc. (ELTX) | M.D., Executive Chairman and Chief Scientific Officer | $484,018 | $1,247,881 |